KALA BIO Soars 12.75% on CHASE Trial Anticipation

KALA BIO's stock surged by 12.75% in pre-market trading on September 2, 2025, driven by anticipation surrounding its upcoming clinical trial data release.

KALA BIO is expected to release topline data from its CHASE trial of KPI-012 by the end of September 2025. The CHASE trial is a Phase 2b study evaluating KPI-012, a lead investigational topical biologic therapy, for the treatment of persistent corneal epithelial defect (PCED). PCED is a rare, non-healing corneal defect that can lead to significant vision loss and currently lacks FDA-approved treatments. The estimated incidence of PCED is 100,000 patients in the US and 238,000 patients combined in the US, EU, and Japan. If the results are positive, the CHASE study could support the submission of a Biologics License Agreement for KPI-012 to the FDA.

KALA BIO's stock has been on a upward trajectory, reflecting investor optimism about the potential success of the CHASE trial. The company's focus on addressing unmet medical needs in the treatment of PCED has garnered significant attention from the investment community. The upcoming data release is expected to provide critical insights into the efficacy and safety of KPI-012, which could have a substantial impact on the company's future prospects.